---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-24-000003"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2024-01-31T23:59:59+00:00"
generated_at: "2026-06-06T13:48:57.733708+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allogene amends Notch collaboration, retains exclusive rights to one CAR target, gives up others

## Summary
- Relinquished exclusive rights to all original CAR targets except one; option limited to one additional target.
- If Notch out-licenses Released Targets, Allogene receives percentage of upfront/milestone payments up to a cap and low single-digit royalties.
- Allogene made ~$22.7M total equity investments in Notch ($5M seed, $15.9M Series A, $1.8M common) and holds ~23% voting interest.
- Amended Agreement includes anti-dilution protections for Allogene's stake in Notch for certain pre-IPO equity financings.

## SEC filing metadata
- accession: 0001737287-24-000003
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2024-01-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000003/0001737287-24-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000003/allo-20240125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-24-000003
- JSON: https://secwatch.observer/filing/0001737287-24-000003.json
- Plain text: https://secwatch.observer/filing/0001737287-24-000003.txt

## Key facts
- Material Agreements
  Allogene Therapeutics, Inc. amended Amended and Restated Collaboration and License Agreement with Notch Therapeutics, Inc. valued at Amended and restated collaboration and license agreement; company relinquished exclusive rights to o (effective 2024-01-25).
  - Action: amendment
  - Agreement: license
  - Counterparty: Notch Therapeutics, Inc.
  - Value: Amended and restated collaboration and license agreement; company relinquished exclusive rights to o
  - Effective: 2024-01-25
  source text: On January 25, 2024, Allogene Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Collaboration and License Agreement (the “Amended Agreement”) with Notch Therapeutics, Inc. (“Notch”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000003/0001737287-24-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.